Vermillion, Inc. is engaged in the discovery, development and commercialization of medical tests that help physicians diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases. The Company�s tests are intended to detect, characterize and stage disease, and to help guide decisions regarding prognosis and patient treatment. The Company�s lead product is OVA1, is an ovarian cancer test system that integrates a software algorithm and blood test. It addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. OVA1 measures the levels of five proteins found in the blood and then uses software called OvaCalc to calculate a single score. A woman�s risk of cancer is measured by using a 0-10 scale versus predetermined cut-off points. Women who are pre-menopausal have a cut off of 5.0 whereas postmenopausal women have a 4.4 cutoff.